{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:47:38Z","timestamp":1771040858956,"version":"3.50.1"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,4,2]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Identify the indication, route of administration and dose for phenobarbital continuous subcutaneous infusion (CSCI) in palliative sedation therapy (PST).<\/jats:p><jats:p>Assess the dosing and continuation of midazolam and levomepromazine in conjunction with phenobarbital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This clinical audit examined inpatient phenobarbital CSCI use for PST from January 2021 to April 2024. Data were retrospectively extracted from electronic medical records (n=23).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most common indication for phenobarbital CSCI was agitation, followed by sedation for non-invasive ventilation withdrawal. Phenobarbital was administered subcutaneously in all cases without adverse systemic or site reactions.<\/jats:p><jats:p>The most common loading dose was 200 mg (50\u2013200\u2009mg), and the most common initiating CSCI dose was 800 mg\/24\u2009hours (400\u20131200\u2009mg\/24\u2009hours). The maximum dose was 1800 mg\/24\u2009hours. The average time to death following start of phenobarbital was 52 hours (4\u2013123\u2009hours). Most patients (n=22) were described as comfortable at death.<\/jats:p><jats:p>Before starting phenobarbital CSCI, all patients were on midazolam CSCI (mean dose 50 mg), which was continued in 14 patients. Seventeen patients received levomepromazine CSCI (mean dose 137 mg), which was continued in 12 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Phenobarbital appears to be an effective medication for PST. However, inconsistencies in dosing, concurrent sedative medication use and standardised protocols highlight areas for improvement in clinical guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2024-005361","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:20:13Z","timestamp":1744219213000},"page":"spcare-2024-005361","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Phenobarbital for inpatient palliative sedation\u2014a clinical audit"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1911-7546","authenticated-orcid":false,"given":"Brendan","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Freeman-Spratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Kasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025040910200426000_spcare-2024-005361v1.1","unstructured":"Safer Care Victoria . Palliative sedation therapy: statewide guidance for Victoria. Safer Care Victoria; 2020."},{"key":"2025040910200426000_spcare-2024-005361v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00006-8"},{"key":"2025040910200426000_spcare-2024-005361v1.3","unstructured":"BC Centre for Palliative Care . BC interprofessional palliative symptom management guidelines. New Westminster, BC, 2024."},{"key":"2025040910200426000_spcare-2024-005361v1.4","unstructured":"NSW Health . Subcutaneous phenobarbital for refractory terminal agitation and uncontrolled seizures (including status epilepticus) in the imminently dying patient. NSW Health; 2023."},{"key":"2025040910200426000_spcare-2024-005361v1.5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/1049909119839695","article-title":"Home Palliative Sedation Using Phenobarbital Suppositories: Time to Death, Patient Characteristics, and Administration Protocol","volume":"36","author":"Setla","year":"2019","journal-title":"Am J Hosp Palliat Care"},{"key":"2025040910200426000_spcare-2024-005361v1.6","unstructured":"End of Life Care, Quality Performance Council . Refractory symptoms and palliative sedation therapy guideline. Fraser Health; 2011."},{"key":"2025040910200426000_spcare-2024-005361v1.7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/15360288.2017.1279502","article-title":"A Review of Agents for Palliative Sedation\/Continuous Deep Sedation: Pharmacology and Practical Applications","volume":"31","author":"Bodnar","year":"2017","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2025040910200426000_spcare-2024-005361v1.8","unstructured":"Wilcock A , Howard P , Charlesworth S . Palliative care formulary. 8th edn. Royal Pharmaceutical Society, 2022."},{"key":"2025040910200426000_spcare-2024-005361v1.9","unstructured":"Cherny N , Smith TJ , Givens J . Palliative sedation. UpToDate; 2024."},{"key":"2025040910200426000_spcare-2024-005361v1.10","unstructured":"ACT, Canberra Health Services . Palliative care sedation therapy. 2021."},{"key":"2025040910200426000_spcare-2024-005361v1.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-003263"},{"key":"2025040910200426000_spcare-2024-005361v1.12","doi-asserted-by":"publisher","DOI":"10.1177\/1049909114555157"},{"key":"2025040910200426000_spcare-2024-005361v1.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2019-002170"},{"key":"2025040910200426000_spcare-2024-005361v1.14","unstructured":"Association for Palliative Medicine of Great Britain and Ireland . Withdrawal of assisted ventilation at the request of a patient with motor neurone disease. 2015."},{"key":"2025040910200426000_spcare-2024-005361v1.15","unstructured":"Specialist Palliative Care Audit and Guidelines Group . Withdrawal of assisted ventilation for hospital inpatients outside of critical care settings. 2020."}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2024-005361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:20:18Z","timestamp":1744219218000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2024-005361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":15,"alternative-id":["10.1136\/spcare-2024-005361"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2024-005361","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}